Disclosed herein is a carbinol compound of formula (I), (for example 5-(benzo[d][1,3]dioxol-5-yl)-3-(2-(5-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-propylphenoxy)pyridin-2-yl)-2-oxoethyl)-5-methylimidazolidine-2,4-dione) wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are Liver X receptor (LXR) agonists and are therefore useful as a preventative and/or therapeutic agent for atherosclerosis； arteriosclerosis such as those resulting from diabetes； dyslipidemia； hypercholesterolemia； lipid-related diseases； inflammatory diseases that are caused by inflammatory cytokines； skin diseases such as allergic skin diseases； diabetes； or Alzheimer's disease.
